# Hinokitiol (4-isopropyltropolone)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/hinokitiol
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 4 / 10
**Category:** Compound
**Also Known As:** β-thujaplicin, 4-isopropyl-2,4,6-cycloheptatrien-1-one, isopropyltropolone, thujaplicin, 2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one, hinoki cypress extract compound

## Overview

Hinokitiol (4-isopropyltropolone) is a natural tropolone compound extracted from the heartwood of Taiwanese hinoki cypress (Chamaecyparis taiwanensis) that exerts [antimicrobial](/ingredients/condition/immune-support), [anti-inflammatory](/ingredients/condition/inflammation), and anticancer effects primarily through iron chelation and SIRT1 pathway activation. Its seven-membered non-benzenoid aromatic ring enables unique metal-binding properties that disrupt iron-dependent bacterial and cancer cell [metabolism](/ingredients/condition/weight-management).

## Health Benefits

• Anti-cancer properties: Shows dose-dependent viability suppression, cell cycle arrest, and apoptosis induction in cervical, breast, and lung cancer cell lines (preliminary in vitro evidence)
• [Anti-inflammatory](/ingredients/condition/inflammation) effects: Inhibits proinflammatory factors (TNF-α, IL-6, PGE2) via SIRT1 activation (preliminary in vitro evidence)
• Cancer stem cell inhibition: Reduces stemness markers (CD44, SOX2, Oct4, Nanog) in breast cancer cells at 50 μM (preliminary in vitro evidence)
• Migration inhibition: Blocks cancer cell migration at 1-5 μM in lung adenocarcinoma cells without affecting viability (preliminary in vitro evidence)
• Iron redistribution: Demonstrated ability to redistribute iron from liver to red blood cells in ferroportin-deficient mice models (preliminary animal evidence)

## Mechanism of Action

Hinokitiol chelates ferric iron (Fe³⁺) via its tropolone ring structure, disrupting iron-dependent enzymatic processes in bacteria and cancer cells including ribonucleotide reductase activity essential for DNA synthesis. It activates SIRT1 ([Sirtuin](/ingredients/condition/longevity)-1), a NAD⁺-dependent deacetylase, which downregulates NF-κB signaling and reduces transcription of pro[inflammatory](/ingredients/condition/inflammation) mediators including TNF-α, IL-6, and COX-2-derived PGE2. In cancer cell lines, it induces G1/S or G2/M cell cycle arrest through modulation of cyclin-dependent kinase inhibitors such as p21 and p27, while simultaneously activating intrinsic apoptotic pathways via caspase-3 and caspase-9 cleavage.

## Clinical Summary

The majority of hinokitiol research consists of in vitro cell culture studies and rodent models, with no published large-scale randomized controlled trials in humans as of 2024. In vitro studies on cervical (HeLa), breast (MCF-7), and lung (A549) cancer cell lines demonstrate dose-dependent viability suppression at concentrations ranging from 10–100 µM, though translating these concentrations to human dosing remains unestablished. [Anti-inflammatory](/ingredients/condition/inflammation) effects were characterized in LPS-stimulated macrophage models showing significant reduction of TNF-α and IL-6 at low micromolar concentrations via SIRT1 activation. Topical formulations containing 0.1–0.5% hinokitiol have been evaluated in small dermatological studies for acne and seborrheic conditions, showing tolerability, but sample sizes were typically under 50 participants, limiting conclusions.

## Nutritional Profile

{"macronutrients": {"protein": "Not applicable", "fiber": "Not applicable", "fats": "Not applicable", "carbohydrates": "Not applicable"}, "micronutrients": {"vitamins": "Not applicable", "minerals": "Not applicable"}, "bioactive_compounds": {"hinokitiol": "Concentration varies depending on the source, typically found in trace amounts in natural sources like the heartwood of the Hinoki tree.", "bioavailability_notes": "Hinokitiol has moderate bioavailability, and its absorption can be influenced by the formulation and delivery method."}}

## Dosage & Preparation

No clinically studied dosages exist due to absence of human trials. In vitro studies use 1-5 μM for migration inhibition, 50 μM for stemness/apoptosis effects, and up to 200 μM for viability studies. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Hinokitiol is generally regarded as safe at low concentrations used in approved cosmetic and oral care products (typically 0.1–1%), with a long history of use in Japanese consumer products. At higher experimental doses, iron-chelating activity poses a theoretical risk of interfering with dietary iron absorption or iron-dependent medications, and caution is warranted in individuals with anemia or iron-deficiency conditions. Due to its iron-chelating mechanism, concurrent use with iron supplements or deferoxamine-class chelators may produce additive or antagonistic effects, though human pharmacokinetic interaction data are absent. Pregnancy and lactation safety has not been established in clinical studies, and use beyond topical cosmetic concentrations is not recommended during pregnancy.

## Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses have been conducted with hinokitiol. All available evidence is limited to preclinical in vitro studies using cancer cell lines and animal models, with concentrations ranging from 1-200 μM showing various anticancer and [anti-inflammatory](/ingredients/condition/inflammation) effects.

## Historical & Cultural Context

No specific historical or traditional medicinal uses are documented in the available research. Hinokitiol is primarily described as a natural compound from Cupressaceae trees without reference to traditional medicine systems.

## Synergistic Combinations

Quercetin, EGCG, Curcumin, Resveratrol, Vitamin C

## Frequently Asked Questions

### What is hinokitiol and where does it come from?

Hinokitiol, chemically named 4-isopropyltropolone, is a naturally occurring tropolone alkaloid first isolated in 1936 from the essential oil of Taiwanese hinoki cypress (Chamaecyparis taiwanensis). It is also found in Western red cedar (Thuja plicata) and other cupressaceous trees, and is commercially synthesized for use in cosmetics, oral care products, and research applications.

### Can hinokitiol kill bacteria and fungi?

Yes, hinokitiol demonstrates broad-spectrum antimicrobial activity against gram-positive bacteria including Staphylococcus aureus and Streptococcus mutans, as well as antifungal activity against Candida albicans, primarily by chelating iron required for microbial growth and disrupting cell membrane integrity. Minimum inhibitory concentrations (MICs) in laboratory studies typically fall in the range of 16–64 µg/mL for common oral and skin pathogens, which is why it is used as a preservative and active agent in toothpastes and skincare products in Japan.

### Does hinokitiol have anticancer properties?

Preliminary in vitro evidence shows hinokitiol suppresses viability of cervical (HeLa), breast (MCF-7), and lung (A549) cancer cell lines in a dose-dependent manner at 10–100 µM concentrations by inducing G1/S cell cycle arrest and activating caspase-3/caspase-9-mediated apoptosis. However, these findings are entirely preclinical and no human clinical trials have been conducted, so hinokitiol cannot be considered a proven cancer treatment or supplement for cancer prevention.

### How does hinokitiol reduce inflammation?

Hinokitiol activates SIRT1 (Sirtuin-1), a NAD⁺-dependent protein deacetylase that suppresses NF-κB transcriptional activity, leading to reduced production of proinflammatory cytokines TNF-α and IL-6, and decreased COX-2-derived prostaglandin E2 (PGE2) in macrophage models. This mechanism has been demonstrated in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophage cell cultures, though comparable human clinical data confirming this anti-inflammatory pathway in vivo are not yet available.

### Is hinokitiol safe to take as an oral supplement?

Hinokitiol has a well-documented safety profile at low concentrations (0.1–1%) in topical and oral care applications approved in Japan and some other markets, but its safety as a standalone oral dietary supplement at therapeutic doses has not been established in human clinical trials. Its iron-chelating activity raises concern for interference with iron homeostasis, particularly in individuals with anemia, and potential interactions with iron supplements or chelation therapies should be considered before use.

### What does current clinical research show about hinokitiol's effectiveness in humans?

Most evidence for hinokitiol comes from laboratory (in vitro) and animal studies rather than human clinical trials, which significantly limits the strength of conclusions about its real-world effectiveness. While preliminary research demonstrates promising anti-cancer, anti-inflammatory, and antimicrobial properties in cell cultures and animal models, robust human trials are needed to confirm dosing, efficacy, and safety profiles. Current human data is sparse, making it difficult to compare hinokitiol's clinical performance to established treatments or other natural compounds with more extensive clinical validation.

### Who should avoid hinokitiol supplementation or use it with caution?

Pregnant and breastfeeding women should avoid hinokitiol due to insufficient safety data in these populations, and individuals with existing cancer should consult their oncologist before use given the experimental nature of cancer research on this ingredient. People taking immunosuppressant medications or those with compromised immune systems should exercise caution, as hinokitiol's antimicrobial and immune-modulating effects may interfere with treatment plans. Additionally, anyone with known hypersensitivity to hinokitiol or structurally related tropolone compounds should avoid supplementation.

### What is the bioavailability of hinokitiol and how is it best absorbed?

Hinokitiol's oral bioavailability and absorption characteristics in humans remain poorly documented, as most research has focused on topical application or in vitro mechanisms rather than pharmacokinetic studies. The compound's lipophilic (fat-soluble) nature suggests it may be better absorbed when taken with dietary fats, though this has not been formally studied in human subjects. Without established pharmacokinetic data, optimal timing relative to meals and the most effective delivery form (essential oil extract, isolated compound, or whole plant derivative) cannot be definitively determined.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*